No headlines found.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Alaunos Therapeutics trades on the NASDAQ stock market under the symbol TCRT.
As of April 10, 2026, TCRT stock price climbed to $2.89 with 29,367 million shares trading.
TCRT has a beta of -1.91, meaning it tends to be less sensitive to market movements. TCRT has a correlation of 0.05 to the broad based SPY ETF.
TCRT has a market cap of $6.45 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, TCRT traded as high as $104.70 and as low as $1.31.
The top ETF exchange traded funds that TCRT belongs to (by Net Assets): VXF.
TCRT has underperformed the market in the last year with a price return of +1.0% while the SPY ETF gained +30.9%. TCRT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.3% and -3.0%, respectively, while the SPY returned -1.8% and +7.2%, respectively.
TCRT support price is $2.66 and resistance is $3.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TCRT shares will trade within this expected range on the day.
